Fredun Pharmaceuticals Limited

FREDUN6

INE194R01017

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 06:00:53 2024-05-17 am EDT			5-day change	1st Jan Change
870.4 ^INR	-1.02%		+4.13%	+0.18%

May. 10	Fredun Pharmaceuticals Limited Proposes Final Dividend for the Financial Year 2023-24	CI
May. 08	Fredun Pharmaceuticals' Net Profit Jumps in Fiscal Q4; Shares Dip 9%	MT

Fredun Pharmaceuticals Limited Receives Approval for Manufacturing Xenografts for Various Dental and Orthopaedic Surgical Appliances from Central Drugs Standard Control Organisation

March 14, 2022 at 08:15 am EDT

Fredun Pharmaceuticals Limited has received the approval for manufacturing Xenografts for various Dental and Orthopaedic surgical appliances from Central Drugs Standard Control Organisation (COSCO), India. With this, the Company aims to penetrate the Dental fraternity across India.

Latest news about Fredun Pharmaceuticals Limited

Fredun Pharmaceuticals Limited Proposes Final Dividend for the Financial Year 2023-24	May. 10	CI
Fredun Pharmaceuticals' Net Profit Jumps in Fiscal Q4; Shares Dip 9%	May. 08	MT
Fredun Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended March 31, 2024	May. 07	CI
Fredun Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	May. 07	CI
Fredun Pharmaceuticals Secures Orders from Sea Countries, Expands Product Development in Veterinary Care, and Advances Orthopaedic Applications	Feb. 12	CI
Fredun Pharmaceuticals Limited Announces Appointment of Ms. Daisy Cyril Dsouza as Additional Independent Director	Nov. 24	CI
Fredun Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 08	CI
Fredun Pharmaceuticals Limited Declared A Dividend At 7% on the Equity Shares of the Company for the Financial Year Ended March 31, 2023	23-09-30	CI
Fredun Pharmaceuticals Limited Proposes Dividend for the Financial Year Ended March 31, 2023	23-09-06	CI
Fredun Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-07-19	CI
Fredun Pharmaceuticals Limited Approves the Resignation of Dr. Chandrakant Shah as Independent Director	23-07-19	CI
Fredun Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023	23-05-25	CI
Fredun Pharmaceuticals Limited Recommends Final Dividend for the Financial Year 2022-23	23-05-24	CI
Fredun Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	23-01-27	CI
Fredun Pharmaceuticals Limited announced that it has received INR 275.691377 million in funding	22-12-26	CI
Fredun Pharmaceuticals Limited Announces Change in Registered Office Address	22-12-13	CI
Fredun Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	22-11-10	CI
Fredun Pharmaceuticals Limited Approves Dividend for the Financial Year Ended March 31, 2022	22-09-30	CI
Fredun Pharmaceuticals Limited announced that it expects to receive INR 284.662157 million in funding	22-08-26	CI
Fredun Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	22-08-12	CI
Fredun Pharmaceuticals Limited Approves Dividend for the Financial Year 2021-22	22-05-16	CI
Fredun Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2022	22-05-16	CI
Fredun Pharmaceuticals Limited Receives Approval for Manufacturing Xenografts for Various Dental and Orthopaedic Surgical Appliances from Central Drugs Standard Control Organisation	22-03-14	CI
Fredun Pharmaceuticals Limited Approves Appointment of Jinkal Shah as Company Secretary and Compliance Officer	22-01-28	CI
Fredun Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	22-01-28	CI

Chart Fredun Pharmaceuticals Limited

Duration

Period

More charts

Company Profile

Fredun Pharmaceuticals Ltd. is an India-based pharmaceutical company. The Company is primarily engaged in the business of pharmaceuticals and healthcare. The Company operates through four segments: Generics (Exports & Fredun Gx), Pet Healthcare (Freossi), Nutraceuticals (Fredun Nutrition) and Cosmeceuticals (Bird and Beauty or BnB). It offers a range of products, including antihypertensive, antidiabetic, antiretroviral drugs (ARVs) and narcotics. It is also engaged in the manufacturing of dietary /herbal supplements, nutraceuticals, and other healthcare products along with animal healthcare products. The Company primarily exports its products to Africa, Southeast Asia, Commonwealth of Independent States (CIS) countries and Latin America.

Sector

Pharmaceuticals

Calendar

2024-08-07 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
FREDUN PHARMACEUTICALS LIMITED	+0.18%	49.5M
ELI LILLY AND COMPANY	+32.09%	694B
NOVO NORDISK A/S	+29.39%	593B
JOHNSON & JOHNSON	-1.34%	371B
MERCK & CO., INC.	+20.34%	331B
ABBVIE INC.	+7.39%	290B
ASTRAZENECA PLC	+14.25%	239B
ROCHE HOLDING AG	-3.03%	209B
NOVARTIS AG	+10.02%	209B
AMGEN INC.	+8.49%	169B

Other Pharmaceuticals